JP Morgan Chase’s Alder Biopharmaceuticals ALDR Stock Holding History

JP Morgan Chase’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-580,000	Closed	-$10.9M	–	6097
2019 Q3	$10.9M	Buy	+580,000	New	+$6.63M	﹤0.01%	2073
2015 Q4	–	Sell	-45,000	Closed	-$1.47M	–	4871
2015 Q3	$1.47M	Buy	+45,000	New	+$1.91M	﹤0.01%	2906

JP Morgan Chase's ALDR Position: Q4 2019 in Review

JP Morgan Chase sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 535,498 shares — an estimated $10.1M sold.

JP Morgan Chase first reported a position in ALDR in Q3 2015 and held it in 17 quarters. The position peaked at $10.4M in Q4 2015. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

JP Morgan Chase reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
JP Morgan Chase sold 535,498 Alder Biopharmaceuticals shares in Q4 2019, an estimated $10.1M.
JP Morgan Chase first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 17 quarters.
JP Morgan Chase's Alder Biopharmaceuticals position peaked at $10.4M in Q4 2015.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.